<DOC>
	<DOCNO>NCT01172912</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . An autologous stem cell transplant may able replace blood-forming cell destroy chemotherapy . PURPOSE : This phase II trial study side effect give high-dose chemotherapy together stem cell transplant see well work treat patient metastatic germ cell tumor respond first-line therapy .</brief_summary>
	<brief_title>High-Dose Chemotherapy Stem Cell Transplant Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded First-Line Therapy</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy high-dose chemotherapy comprise carboplatin etoposide ( CE ) combination autologous hematopoietic stem cell transplantation use CE regimen initial salvage treatment patient relapse refractory , metastatic germ cell tumor respond first-line treatment . - To evaluate toxicity associate regimen patient . - To evaluate biological correlate outcome patient available tissue pre- post-treatment . OUTLINE : - Conventional-dose chemotherapy : Patients receive ifosfamide day 1 2 , follow cisplatin etoposide day 3-5 , dexamethasone day 1-5 . Patients undergo leukapheresis daily stem cell harvest . Patients also receive conventional filgrastim ( G-CSF ) subcutaneously ( SC ) day begin 48 hour completion chemotherapy adequate collection stem cell obtain . Treatment repeat every 21 day 1 2 course . - High-dose ( HD ) chemotherapy : Patients receive HD carboplatin etoposide day day 1-3 . Treatments repeat every 30-40 day 2 course . - Autologous hematopoietic stem cell transplantation : Patients undergo reinfusion autologous stem cell day 6 ( HD chemotherapy day 1-5 ) . Patients receive one dose pegfilgrastim SC begin 6 hour completion stem cell infusion conventional filgrastim SC daily begin 4 day completion stem cell infusion continue blood count recover .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm germ cell tumor ( GCT ) base pathologic review INT Milan Metastatic disease Relapsed refractory disease Prior chemotherapy treatment GCT without pathologic diagnosis due unequivocal clinical evidence GCT urgent need start therapy ( elevate alphafetoprotein [ AFP ] human chorionic gonadotropin [ HCG ] pattern metastasis consistent GCT high tumor burden ) allow Unequivocal progression measurable disease , consist abnormality 2dimensional image raise tumor marker , follow 1 line cisplatinbased chemotherapy document either follow : Tumor biopsy new , grow , unresectable lesion demonstrate viable nonteratomatous GCT ( enrollment study adjuvant treatment resection viable GCT allow ) Increasing abnormally elevate serum tumor marker ( HCG AFP ) ( increase lactate dehydrogenase [ LDH ] alone constitute progressive disease ) Received ≥ 3 ≤ 6 , cisplatinbased chemotherapy course part firstline ( initial ) chemotherapy ≤ 6 cisplatinbased chemotherapy course Brain metastasis allow May treat radiotherapy and/or surgery concurrently cisplatin , ifosfamide , etoposide regimen Radiotherapy give concurrently mobilization phase/leukapheresis highdose carboplatin etoposide PATIENT CHARACTERISTICS : WBC ≥ 2,000/µL ANC ≥ 1,500/µL Platelet count ≥ 100,000/µL Creatinine clearance ≥ 50 cc/min ( unless renal dysfunction due tumor obstruct ureter , case eligibility determine principal investigator ) AST/ALT &lt; 2 time upper limit normal ( ULN ) ( &lt; 5 time ULN due hepatic metastasis ) Total bilirubin &lt; 1.5 time ULN Ejection fraction ≥ 50 % echocardiogram Negative serology follow infectious disease : HIV type 1 2 Hepatitis B surface antigen ( active carrier ) Hepatitis C Cytomegalovirus ( serum Ag p65 ± PCR confirmation principal investigator discretion ) PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior surgery At least 3 week since prior chemotherapy No prior highdose chemotherapy peripheral blood stem cell rescue No 1 prior chemotherapy regimen metastatic disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>testicular mature teratoma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>testicular immature teratoma</keyword>
</DOC>